Olivia C. Ware - 04 May 2022 Form 4/A - Amendment Insider Report for Revance Therapeutics, Inc.

Role: Director
Signature: /s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 04 May 2022
Net transactions value: $0
Form type: 4/A - Amendment
Filing time: 13 May 2022, 18:16:15 UTC
Date Of Original Report: 06 May 2022
Previous filing: 07 May 2021
Next filing: 17 May 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RVNC	Stock Option (Right to buy)	Award	$0	+10,756		$0.000000	10,756	04 May 2022	Common Stock	10,756	$18.12	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to the stock option shall vest on the one year anniversary, May 4, 2023, subject to Ms. Ware's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) through such vesting date. The stock option represents an annual grant pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy

Remarks:

The original Form 4, filed on May 6, 2022, inadvertently listed the incorrect number of options granted to the Reporting Person on May 4, 2022 due to an administrative error. This Form 4/A is being filed to correct the number of shares underlying the stock option originally reported.